Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 419,400 shares, a decline of 25.6% from the February 28th total of 564,000 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 0.4 days.

Vigil Neuroscience Stock Down 6.8 %

Shares of NASDAQ:VIGL opened at $1.78 on Tuesday. The company has a market cap of $83.08 million, a price-to-earnings ratio of -0.86 and a beta of 1.82. The business has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.65. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). Analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Analyst Upgrades and Downgrades

VIGL has been the topic of a number of analyst reports. William Blair started coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Wedbush lowered their price target on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, March 14th. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, HC Wainwright decreased their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $16.25.

Hedge Funds Weigh In On Vigil Neuroscience

Several large investors have recently bought and sold shares of the stock. Woodline Partners LP raised its position in shares of Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after buying an additional 344,614 shares during the last quarter. Blair William & Co. IL acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $551,000. Renaissance Technologies LLC increased its stake in Vigil Neuroscience by 698.5% during the fourth quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock valued at $624,000 after acquiring an additional 321,300 shares during the period. abrdn plc raised its holdings in Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after acquiring an additional 293,461 shares in the last quarter. Finally, Trustees of Columbia University in the City of New York acquired a new position in Vigil Neuroscience in the 4th quarter valued at approximately $328,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.